Free Newsletter
Generics depress profits at Walgreen's
The generic-drug hammer has fallen again, and this time it hit a retail pharmacy. Walgreen's fiscal fourth-quarter profit dropped by almost 4 percent in part because of generics.
Simvastatin--the generic form of the Merck cholesterol drug Zocor--was a particular problem. The company filled three times as many simvastatin scrips this quarter than it did during the same period last year, but made virtually the same amount of money because of tightened reimbursements from health plans. Maybe Walgreen's and Merck can cry in their coffee together.
- see Walgreen's press release
- read the New York Times article
Related Articles:
Generics beat down drug price inflation
Switching to generic statins not so healthy
Merck slashes Zocor price as patent expires
Paid Research Reports
- Trends in mHealth and Telemedicine
- The Global Aesthetic Dermatology Market Outlook
- Future Directions in Regenerative Medicine
- Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
- Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
- Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline


SHARE
WITH: